

Asarina Pharma sells Sepranolone assets to Relmada Therapeutics

Stockholm, 7 February 2025. Asarina Pharma AB (“Asarina” or “the Company”) today announces that it has signed an Asset Purchase Agreement with Relmada Therapeutics Inc. (US) for the sale of its compound Sepranolone. Under the terms of the agreement, Relmada acquires all rights to Sepranolone, enabling it to continue the clinical development of Sepranolone in Tourette Syndrome (TS) and potentially other neurological indications.

Relmada, a company focused on central nervous system (CNS) disorders, plans to take Sepranolone forward into a phase IIb study in TS.

Peter Nordkild, CEO, comments: “We are very pleased that Sepranolone and our Tourette project have found a new home. In the phase IIa study, Sepranolone demonstrated promising effects in TS and a strong safety profile without CNS off-target effects. We strongly believe that it has the potential to become a first-line pharmaceutical therapy for TS, significantly improving quality of life for TS patients. While we would have liked Asarina to continue the development of Sepranolone, we are confident that Relmada is well suited to bring the compound forward towards regulatory approval and commercialization.

Following the transfer of assets to Relmada, the Board of Directors intends to convene an Extraordinary General Meeting and propose to the shareholders that Asarina Pharma be liquidated.

For further information, please contact:

- Peter Nordkild, CEO: +45 2547 1646
- Paul de Potocki, chairman of the board: +46 70-669 9618

Asarina Pharma AB (publ) is a Swedish biotech company and is based in Solna. Asarina Pharma AB (publ)

For further information, see our website: www.asarinapharma.se.

Attachments

[Asarina Pharma sells Sepranolone assets to Relmada Therapeutics](#)